Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (CRISP)
Sponsor: AIO-Studien-gGmbH
Listed as NCT02622581, this observational or N/A phase trial focuses on Metastatic Non-small Cell Lung Cancer (NSCLC) and Non Small Cell Lung Cancer Stage III and remains actively recruiting participants. Sponsored by AIO-Studien-gGmbH, it has been updated 19 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
19 versions recorded-
Oct 2025 — Present [monthly]
Recruiting
-
Mar 2025 — Oct 2025 [monthly]
Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Mar 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 14 earlier versions
-
Nov 2023 — Mar 2024 [monthly]
Recruiting
-
Sep 2022 — Nov 2023 [monthly]
Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Recruiting
-
Dec 2021 — Jun 2022 [monthly]
Recruiting
-
May 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
May 2020 — Nov 2020 [monthly]
Recruiting
-
Nov 2019 — May 2020 [monthly]
Recruiting
-
Jun 2018 — Nov 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AIO-Studien-gGmbH
- Amgen
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene Corporation
- Daiichi Sankyo
- Eli Lilly and Company
- Gilead Sciences
- GlaxoSmithKline
- Janssen-Cilag G.m.b.H
- Merck Sharp & Dohme LLC
- Novartis Pharmaceuticals
- Pfizer
- Regeneron Pharmaceuticals
- Roche Pharma AG
- Takeda
- iOMEDICO AG
For direct contact, visit the study record on ClinicalTrials.gov .